|
FDA Moves to Clear Forgotten ANDAs As Congress Nears GDUFA Passage
The FDA’s Office of Generic Drugs (OGD) appears to be taking the first steps to whittling down its almost 3,000-long ANDA backlog, telling drugmakers it will discard 364 pending generic-drug applications unless told otherwise.
This article is viewable by subscribers only. To view this article, please select an option below.
|
Subscribe
Archives